Company / Operating Income
Amphstar Pharmaceuticals, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$140.4M
FY2025
5-year range
$69.9M / $205.4M
FY2021-FY2025
Trend
-31.7%
vs FY2024
Sector context
#31 of 204
Health Care
What the data says
Amphstar Pharmaceuticals, Inc.'s operating income of $140M is higher than 85% of companies in the Health Care sector (FY2025). Declined from $197M to $140M over the past 2 years.
Based on SEC 10-K filings.
$140M in FY2025 with a 5-year CAGR of +66.6%. Top quartile in the Health Care sector.
Declined from $197M to $140M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- +9.3%
- 5-Year CAGR
- +66.6%
- 10-Year CAGR
- -
Sector benchmark
Top 15% in Health CareTop 15% of 204This company $140.4M Sector average $107.7M
▼
+30.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +66.6%, indicating consistent growth.
- In FY2025, operating income decreased 31.7% year-over-year.
- Ranks #31 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2024.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $140.4M | -31.7% |
| FY2024 | $205.4M | +4.3% |
| FY2023 | $197.0M | +83.2% |
| FY2022 | $107.5M | +53.8% |
| FY2021 | $69.9M | +538.0% |
| FY2020 | $11.0M | +28187.2% |
| FY2019 | -$39.0K | +99.5% |
| FY2018 | -$8.6M | -579.5% |
| FY2017 | -$1.3M | -108.3% |
| FY2016 | $15.4M | +322.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026